Recurrence risk after resection of gastrointestinal stromal tumors: Size is not all that matters... the consequences of tumor rupture

Dale Han, Jeremiah Deneve, Ricardo J. Gonzalez

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that most commonly have activating mutations in KIT. Recurrence after complete resection remains a significant problem, and the ability to identify patients at high risk for recurrence would allow for selective use of adjuvant therapies such as imatinib in patients who may garner the most benefit. Initial staging systems stratified recurrence risk by tumor size and mitotic index, whereas subsequent staging systems also included tumor location. However, other clinical factors may influence prognosis and the risk for tumor recurrence after surgery. The purpose of this article is to highlight tumor rupture as an additional risk factor that should be considered when assessing for recurrence risk. Tumor rupture is associated with decreased survival and increased recurrence rates, but it is not universally included in current staging systems. Patients with ruptured GISTs may not meet the risk criteria elaborated in some current staging systems, yet these patients are at high risk for tumor recurrence and may benefit from adjuvant imatinib therapy. A fundamental understanding of all the risk factors for tumor recurrence, including tumor rupture, and appropriate consideration for adjuvant therapy through a multidisciplinary approach are requisite for the maximal prevention of disease recurrence.

Original languageEnglish (US)
Pages (from-to)74-79
Number of pages6
JournalAmerican Surgeon
Volume78
Issue number1
StatePublished - Jan 1 2012

Fingerprint

Gastrointestinal Stromal Tumors
Rupture
Recurrence
Neoplasms
Mitotic Index
Therapeutics
Mutation
Survival

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Recurrence risk after resection of gastrointestinal stromal tumors : Size is not all that matters... the consequences of tumor rupture. / Han, Dale; Deneve, Jeremiah; Gonzalez, Ricardo J.

In: American Surgeon, Vol. 78, No. 1, 01.01.2012, p. 74-79.

Research output: Contribution to journalReview article

@article{eb6a7e20d5f34f77abe224b34f9d5b64,
title = "Recurrence risk after resection of gastrointestinal stromal tumors: Size is not all that matters... the consequences of tumor rupture",
abstract = "Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that most commonly have activating mutations in KIT. Recurrence after complete resection remains a significant problem, and the ability to identify patients at high risk for recurrence would allow for selective use of adjuvant therapies such as imatinib in patients who may garner the most benefit. Initial staging systems stratified recurrence risk by tumor size and mitotic index, whereas subsequent staging systems also included tumor location. However, other clinical factors may influence prognosis and the risk for tumor recurrence after surgery. The purpose of this article is to highlight tumor rupture as an additional risk factor that should be considered when assessing for recurrence risk. Tumor rupture is associated with decreased survival and increased recurrence rates, but it is not universally included in current staging systems. Patients with ruptured GISTs may not meet the risk criteria elaborated in some current staging systems, yet these patients are at high risk for tumor recurrence and may benefit from adjuvant imatinib therapy. A fundamental understanding of all the risk factors for tumor recurrence, including tumor rupture, and appropriate consideration for adjuvant therapy through a multidisciplinary approach are requisite for the maximal prevention of disease recurrence.",
author = "Dale Han and Jeremiah Deneve and Gonzalez, {Ricardo J.}",
year = "2012",
month = "1",
day = "1",
language = "English (US)",
volume = "78",
pages = "74--79",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "1",

}

TY - JOUR

T1 - Recurrence risk after resection of gastrointestinal stromal tumors

T2 - Size is not all that matters... the consequences of tumor rupture

AU - Han, Dale

AU - Deneve, Jeremiah

AU - Gonzalez, Ricardo J.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that most commonly have activating mutations in KIT. Recurrence after complete resection remains a significant problem, and the ability to identify patients at high risk for recurrence would allow for selective use of adjuvant therapies such as imatinib in patients who may garner the most benefit. Initial staging systems stratified recurrence risk by tumor size and mitotic index, whereas subsequent staging systems also included tumor location. However, other clinical factors may influence prognosis and the risk for tumor recurrence after surgery. The purpose of this article is to highlight tumor rupture as an additional risk factor that should be considered when assessing for recurrence risk. Tumor rupture is associated with decreased survival and increased recurrence rates, but it is not universally included in current staging systems. Patients with ruptured GISTs may not meet the risk criteria elaborated in some current staging systems, yet these patients are at high risk for tumor recurrence and may benefit from adjuvant imatinib therapy. A fundamental understanding of all the risk factors for tumor recurrence, including tumor rupture, and appropriate consideration for adjuvant therapy through a multidisciplinary approach are requisite for the maximal prevention of disease recurrence.

AB - Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors that most commonly have activating mutations in KIT. Recurrence after complete resection remains a significant problem, and the ability to identify patients at high risk for recurrence would allow for selective use of adjuvant therapies such as imatinib in patients who may garner the most benefit. Initial staging systems stratified recurrence risk by tumor size and mitotic index, whereas subsequent staging systems also included tumor location. However, other clinical factors may influence prognosis and the risk for tumor recurrence after surgery. The purpose of this article is to highlight tumor rupture as an additional risk factor that should be considered when assessing for recurrence risk. Tumor rupture is associated with decreased survival and increased recurrence rates, but it is not universally included in current staging systems. Patients with ruptured GISTs may not meet the risk criteria elaborated in some current staging systems, yet these patients are at high risk for tumor recurrence and may benefit from adjuvant imatinib therapy. A fundamental understanding of all the risk factors for tumor recurrence, including tumor rupture, and appropriate consideration for adjuvant therapy through a multidisciplinary approach are requisite for the maximal prevention of disease recurrence.

UR - http://www.scopus.com/inward/record.url?scp=84857070308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857070308&partnerID=8YFLogxK

M3 - Review article

C2 - 22273319

AN - SCOPUS:84857070308

VL - 78

SP - 74

EP - 79

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 1

ER -